$477M deal enhances organ preservation and healthcare innovation capabilities.
Getinge has finalized its $477 million acquisition of Paragonix Technologies, a Massachusetts-based company specializing in organ preservation systems. This strategic move strengthens Getinge’s position in the global transplant market.
Advancing Organ Transplant Innovation
Paragonix’s portfolio includes organ preservation systems for the heart, liver, pancreas, and lungs, combining hypothermic preservation technology with digital tools for tracking and monitoring. The integration with Getinge’s resources aims to accelerate access to these critical technologies worldwide.
“Paragonix’s solutions, paired with Getinge’s expertise in heart and lung support, create a powerful portfolio for addressing global transplant needs,” the company stated.
Financial and Strategic Details
Getinge paid $253 million upfront, with potential earn-out payments of up to $224 million tied to regulatory and financial milestones through 2026.
The acquisition aligns with Getinge’s strategy to foster innovation by combining organ containment and blood perfusion technologies, paving the way for transformative healthcare solutions.
Follow MEDWIRE.AI for updates on MedTech innovations and acquisitions.
